ライフサイエンスコーパス: tamsulosin

1 aract surgery after the use of alfuzosin and tamsulosin.

2 plus tamsulosin, 0.4%; tolterodine ER, 0.5%; tamsulosin, 0%; and placebo, 0%).

3 ventions: Ciprofloxacin, 500 mg twice daily; tamsulosin, 0.4 mg once daily; a combination of the 2 dr

4 catheterization was low (tolterodine ER plus tamsulosin, 0.4%; tolterodine ER, 0.5%; tamsulosin, 0%;

5 Tamsulosin 400 mug and nifedipine 30 mg are not effectiv

6 assigned by a remote randomisation system to tamsulosin 400 mug, nifedipine 30 mg, or placebo taken d

7 nst prostate tumor epithelial cells, whereas tamsulosin, a sulfonamide-based alpha1-adrenoceptor anta

8 eptor antagonists, doxazosin, terazosin, and tamsulosin, against prostate cancer cell growth.

9 symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin and silodosin.

10 Tamsulosin, alfuzosin slow release and silodosin do not

11 ularly prevalent among patients treated with tamsulosin, an alpha-1A blocker prescribed for the treat

12 Although both tamsulosin and alfuzosin significantly increase the risk

13 We studied 15 and 25 patients administered tamsulosin and alfuzosin, respectively, as well as 25 co

14 e treatment and placebo (p=0.78), or between tamsulosin and nifedipine (p=0.77).

15 cluded that the smooth muscle relaxant drugs tamsulosin and nifedipine assisted stone passage for peo

16 strong association exists between the use of tamsulosin and the occurance of intraoperative floppy ir

17 vir led to increased exposures of doxazosin, tamsulosin, and/or quetiapine, resulting in additional a

18 Patients receiving tolterodine ER plus tamsulosin compared with placebo experienced significant

19 Patients receiving tolterodine ER plus tamsulosin demonstrated significant improvements on the

20 Ciprofloxacin and tamsulosin did not substantially reduce symptoms in men

21 evere IFIS was noted in 34.3% (24/70) of the tamsulosin eyes and in 16.3% (7/43) of the alfuzosin eye

22 gest that treatment with tolterodine ER plus tamsulosin for 12 weeks provides benefit for men with mo

23 weeks, compared with 307 (81%) of 378 in the tamsulosin group (adjusted risk difference 1.3% [95% CI

24 eters were reduced significantly only in the tamsulosin group (by 1.09+/-0.31 mm [P=.001] and by 0.89

25 y reduced by 0.70+/-0.20 m/s (P=.001) in the tamsulosin group and by 0.54+/-0.18 m/s (P=.004) in the

26 A total of 226 eyes (70 in the tamsulosin group, 43 in the alfuzosin group, and 113 in

27 er stimulation (5.23+/-2.42%, P=.035) in the tamsulosin group.

28 poptosis in a dose-dependent manner, whereas tamsulosin had no effect on prostate cell growth.

29 Patients treated with tamsulosin have a higher risk of wound dehiscence after

30 tiomers 20, 23, and 24 were less potent than tamsulosin in inhibiting contractions of rat prostate ti

31 tdilation pupil dynamics, demonstrating that tamsulosin is more potent than alfuzosin in inducing int

32 but much more selective at alpha(1a)-AR than tamsulosin (K(i) = 0.13 nM, alpha(1b)/alpha(1a) = 14.8,

33 4 mg of tolterodine ER (n = 217), 0.4 mg of tamsulosin (n = 215), or both tolterodine ER plus tamsul

34 losin (n = 215), or both tolterodine ER plus tamsulosin (n = 225) for 12 weeks.

35 nistering an alpha-1A-adrenergic antagonist, Tamsulosin, on urodynamics.

36 ofloxacin (P = 0.15) or tamsulosin versus no tamsulosin (P > 0.2).

37 eiving placebo (P<.001), 146 (71%) receiving tamsulosin (P=.06 vs placebo), or 135 (65%) receiving to

38 172 men (80%) receiving tolterodine ER plus tamsulosin reported treatment benefit by week 12 compare

39 vere IFIS statistically was more likely with tamsulosin than with alfuzosin (P = 0.036).

40 ability of doxazosin and terazosin (but not tamsulosin) to suppress prostate cancer cell growth in v

41 ns, and iris hook use was similar in the two tamsulosin treated group.

42 conventional repeated eyedrops regiment for tamsulosin treated patients.

43 ence interval: 1.24-11.67, P = .0194) in the tamsulosin-treated group.

44 se sponge on perioperative pupil diameter in tamsulosin-treated patients undergoing elective cataract

45 Patients treated with tamsulosin underwent subgroup analysis.

46 Carefully taking a history of tamsulosin use before cataract surgery is advised so tha

47 y combined with another intraocular surgery, tamsulosin use) and surgeon-related factors (low surgica

48 oxacin versus no ciprofloxacin (P = 0.15) or tamsulosin versus no tamsulosin (P > 0.2).

49 Patients using tamsulosin were dilated either with mydriatic-cocktail s